Evidence map›Paper›PMID 41331616›Full record

Observational studyCardiovascular diabetology2025

Prognostic implications of quantified coronary atherosclerosis and myocardial perfusion in diabetes.

Matias Mäenpää, Ruurt A Jukema, Pepijn van Diemen, Sarah Bär, Pieter G Raijmakers, Ralf Sprengers, Roel S Driessen, Jeroen J Bax, Paul Knaapen, Juhani Knuuti and 3 more

Abstract readObservational Study
In one paragraph

Observational study in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matias MäenpääTurku PET Centre, Turku University Hospital and University of Turku, P.O. Box 52, 20521, Turku, Finland. matmae@utu.fi.
Ruurt A JukemaDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pepijn van DiemenDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Sarah BärTurku PET Centre, Turku University Hospital and University of Turku, P.O. Box 52, 20521, Turku, Finland.
Pieter G RaijmakersDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Ralf SprengersDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Roel S DriessenDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Jeroen J BaxDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Paul KnaapenDepartment of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Juhani KnuutiTurku PET Centre, Turku University Hospital and University of Turku, P.O. Box 52, 20521, Turku, Finland.
Ibrahim DanadDepartment of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Antti SarasteTurku PET Centre, Turku University Hospital and University of Turku, P.O. Box 52, 20521, Turku, Finland.
Teemu MaaniittyTurku PET Centre, Turku University Hospital and University of Turku, P.O. Box 52, 20521, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronary artery disease (CAD) is a major contributor to cardiovascular events in individuals with diabetes. Quantification of coronary atherosclerotic burden is now feasible from coronary computed tomography angiography (CTA) whereas positron emission tomography (PET) enables quantitative assessment of myocardial perfusion. We studied the prognostic implications of quantitatively measured coronary plaque burden and myocardial perfusion in diabetic vs. non-diabetic patients with suspected CAD.

methodsIn this observational cohort study, 1311 symptomatic patients with suspected CAD underwent coronary CTA and [

resultsAmong the 1311 patients, 251 (19%) had diabetes and 134 (10%) experienced an adverse event during follow-up. The annual event rate was low (0.8% [95% CI 0.6-1.1%]) in non-diabetic patients with normal myocardial perfusion and increased significantly with the presence of either diabetes (2.3% [95% CI 1.4-3.8%]), abnormal perfusion (2.6% [95% CI 2.1-3.3%]), or both (3.2% [95% CI 2.1-4.8%]) (p < 0.001). Among patients with normal myocardial perfusion, those with diabetes had two-fold PAV as compared with non-diabetic individuals (median 8.2% vs. 4.1%, p < 0.001). In multivariable Cox regression models, both PAV (HR 1.03 [95% CI 1.01-1.05] per 1% increase, p < 0.001) and regional sMBF (HR 1.04 [95% CI 1.01-1.07] per 0.1 ml/g/min decrease, p = 0.016) were independent predictors of adverse outcome in non-diabetic patients. In diabetic patients, only PAV (HR 1.04 [95% CI 1.01-1.07], p = 0.014) was predictive, whereas sMBF was not.

conclusionsCoronary atherosclerotic plaque burden appears as an important predictor of long-term cardiovascular outcomes both in diabetic and non-diabetic patients. In patients with diabetes, normal myocardial perfusion does not necessarily imply low event risk, partly attributable to higher coronary plaque burden. Quantitative imaging methods for detailed CAD phenotyping shed light on the complex relationship between diabetes and clinical outcomes.

Indexed as

Computed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseCoronary CirculationDiabetes MellitusMyocardial Perfusion ImagingPlaque, AtheroscleroticAgedAngina, UnstableFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisRisk AssessmentCardiac complicationsCoronary artery diseaseCoronary computed tomography angiographyDiabetesPositron emission tomographyPrognosis

Identifiers

PMID41331616
PMCPMC12676773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.